Augusta University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Augusta University sits in the top decile of US sponsors by registered trial count (#231 of 15,742 sponsors by registered trial count).
Augusta University: 106 sponsored US clinical trials, 13 recruiting.
Augusta University sponsors 106 registered US clinical trials on ClinicalTrials.gov, 13 of them currently recruiting, and 71 completed. 11 of these trials are in Phase 3-4 (later-stage) and 23 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hypertension, with 4 trials.
Top-decile sponsor footprint
Augusta University ranks in the top decile of sponsors by registered trial count (#231 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
71 of 83 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
106 total, page 1 of 3
A Trial to Test Intermittent Deep Brain Stimulation of Nucleus Basalis of Meynert to Treat Alzheimers.
NCT07218081
Transition From Donor Milk: a Feasibility Study
NCT06514014
Effects of Home Base Whole-body Vibration in Osteoarthritis. (VIBE-Rx2)
NCT06058169
Lifestyle Intervention for Healthy Change
NCT05956574
BREATHE Free: a Pilot Feasibility Trial
NCT06862050
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
NCT06142396
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
NCT06588413
Virtual Reality During Exercise Testing
NCT06464406
Blood Conservation in Patients (3.5-12kg) Undergoing Congenital Cardiac Surgery
NCT05881564
Home Biofeedback Therapy for Dyssynergic Defecation, Fecal Incontinence and Urinary Incontinence
NCT05771597
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
NCT05143840
Health Benefits of Whole-body Vibration
NCT05097885
Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1
NCT04449198
CO-creating Novel, Feasible, and Inclusive Research Methods
NCT07489144
The Effect of Low Frequency Soundwave Stimulation on Chemotherapy Induced Peripheral Neuropathy
NCT05980169
Does EVOO Induce Gene and Metabolic Changes in Healthy Subjects
NCT05929924
Genetic Testing in African Americans
NCT05591131
Adiposity and Endothelin Receptor Function
NCT03583866
Endothelin Receptor Function and Acute Stress
NCT02116335
Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF
NCT02690064
Nitric Oxide Bioavailability and Early Life Stress (NO-Stress)
NCT02115724
A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia
NCT06907992
The Impact of Meditation on Anxiety and Post-Operative Pain in Pediatric Patients Undergoing Urological Surgery
NCT06858267
Effects of Peanut Butter on Sleep Quality and Daily Energy Levels in Fire Fighters
NCT06364202
Firdapse for Post-BOTOX Vocal Weakness
NCT05123053
Physical Activity to Reduce Diabetes Risk in Serious Mental Illness
NCT05293587
A Smartphone-Based Approach to Improved Breast-Feeding Rates And Self-Efficacy
NCT04816383
Fetal Heart Rate Changes and Labor Neuraxial Analgesia: a Machine Learning Approach
NCT05399979
Thoracic Splanchnic Magnetic Neuromodulation Therapy (ThorS-MagNT) for Grade 3 Diabetic Gastroparesis: Pilot Study
NCT04706832
Nasal Irrigation to Reduce COVID-19 Morbidity
NCT04559035
Contribution of Dolutegravir to Obesity and Cardiovascular Disease
NCT04340388
Anxiety Level Assessment of Anesthesia Providers During COVID-19 Pandemic
NCT05212909
A Technological Approach to Improved Breastfeeding Rates and Self-Efficacy
NCT05673317
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
NCT04173338
Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer
NCT04173325
Remote Outpatient Temperature Monitoring for Early Detection of Febrile Neutropenia After Chemotherapy
NCT04081753
Color Doppler and Peripheral Venous Catheters
NCT03889678
Stellate Ganglion Block in Head and Neck Cancer Surgery
NCT03714906
Post-dural Puncture Headache: A Retrospective Study
NCT03790124
Accuracy of Current Techniques in Quantifying Ketone Levels
NCT06909331
Dental Intervention Plan for Chronic Kidney Disease Patients Awaiting or With Kidney Transplant
NCT04020458
Chemotherapy-Induced Peripheral Neuropathy-Essential Oil Intervention
NCT03449303
Evaluation of the Effect of Body Mass Index on Gastric Volume With Ultrasound in Term Pregnant Women
NCT03555604
Color Doppler Ultrasound to Locate Needle in Labor Epidural
NCT03596333
Thromboelastogram in Postdelivery Preeclamptic Patients
NCT03555630
Evaluation of Changes of Venous Return After Spinal and Epidural Analgesia and Anesthesia by Ultrasound Guided Vena Cava Diameter Measurement
NCT03555799
Estrogen and Diabetes
NCT03436992
Intrapartum Epidural Catheter Displacement: Dressing Methods
NCT03574441
Parkinson's Disease and Digestive Health
NCT04032262
Effects of Exogenous Ketones in Healthy Young Adults
NCT03452761
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 10 |
| Phase 3 | 4 |
| Phase 4 | 7 |
Therapeutic Areas
What is open in the Augusta University pipeline
13 recruiting of 106 indexed (12% open); 71 completed (67%).
Phase mix: 11 late (III/IV) vs 23 early (I/II) (early-phase heavy).
Top condition: Hypertension (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Augusta University: open-pipeline peers nationwide
Peers matched on 106 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
Augusta University sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 106 trials (± recruiting share)
- Corewell Health East · 106 trials · 9% recruiting
- University of Delaware · 106 trials · 23% recruiting
- Geisinger Clinic · 107 trials · 9% recruiting
- St. Louis University · 107 trials · 11% recruiting
Sponsors near 12% open enrollment (± trial volume)
- University of Iowa · 12% recruiting · 228 trials
- National Institute of Mental Health (NIMH) · 12% recruiting · 343 trials
- Daiichi Sankyo · 12% recruiting · 236 trials
- Friends Research Institute · 12% recruiting · 41 trials
Related
What to do with this Augusta University page
106 registered trials is a research-attention snapshot, not an endorsement of Augusta University or any single study.
- 13 of Augusta University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Hypertension is the condition Augusta University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hypertension trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Augusta University pipeline card: 106 registered trials from official public datasets.Report a data error.